| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9345772 | MYLAN | Liquid levothyroxine formulations |
Feb, 2035
(10 years from now) | |
Ermeza is owned by Mylan.
Ermeza contains Levothyroxine Sodium.
Ermeza has a total of 1 drug patent out of which 0 drug patents have expired.
Ermeza was authorised for market use on 29 April, 2022.
Ermeza is available in solution;oral dosage forms.
The generics of Ermeza are possible to be released after 27 February, 2035.
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 29 April, 2022
Treatment: NA
Dosage: SOLUTION;ORAL
More Information on Dosage
ERMEZA family patents
